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Acute pulmonary inflammation is characterized by migration of polymorphonuclear neutro-
phils (PMNs) into the different compartments of the lung, passing an endothelial and epithe-
lial barrier. Recent studies showed evidence that phosphodiesterase (PDE)4-inhibitors
stabilized endothelial cells. PDE4B and PDE4D subtypes play a pivotal role in inflammation,
whereas blocking PDE4D is suspected to cause gastrointestinal side effects. We thought to
investigate the particular role of the PDE4-inhibitors roflumilast and rolipram on lung epithe-
lium. Acute pulmonary inflammation was induced by inhalation of LPS. PDE4-inhibitors
were administered i.p. or nebulized after inflammation. The impact of PDE4-inhibitors on
PMNmigration was evaluated in vivo and in vitro. Microvascular permeability, cytokine lev-
els, and PDE4B and PDE4D expression were analyzed. In vivo, both PDE4-inhibitors de-
creased transendothelial and transepithelial migration even when administered after
inflammation, whereas roflumilast showed a superior effect compared to rolipram on the ep-
ithelium. Both inhibitors decreased TNFα, IL6, and CXCL2/3. CXCL1, the strong PMN che-
moattractant secreted by the epithelium, was significantly more reduced by roflumilast. In
vitro assays with human epithelium also emphasized the pivotal role of roflumilast on the ep-
ithelium. Additionally, LPS-induced stress fibers, an essential requirement for a direct mi-
gration of PMNs into the alveolar space, were predominantly reduced by roflumilast.
Expression of PDE4B and PDE4D were both increased in the lungs by LPS, PDE4-inhibi-
tors decreased mainly PDE4B. The topical administration of PDE4-inhibitors was also effec-
tive in curbing down PMNmigration, further highlighting the clinical potential of these
compounds. In pulmonary epithelial cells, both subtypes were found coexistent around the
nucleus and the cytoplasm. In these epithelial cells, LPS increased PDE4B and, to a lesser
extend, PDE4D, whereas the effect of the inhibitors was prominent on the PDE4B subtype.
In conclusion, we determined the pivotal role of the PDE4-inhibitor roflumilast on lung epi-
thelium and emphasized its main effect on PDE4B in hyperinflammation.
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Introduction
Acute pulmonary inflammation and its more severe form acute respiratory distress syndrome
(ARDS) are often seen in critically ill patients leading to hypoxemic respiratory failure with a
40% mortality [1].
In pulmonary inflammation, polymorphonuclear neutrophil granulocytes (PMNs) migrate
to the site of inflammation: from the blood to the interstitium of the lung by passing the endo-
thelial barrier—followed by a transepithelial migration from the interstitium into the alveolar
space. These two migration steps underlie different regulations [2]. Migration of PMNs is nec-
essary for host defense but excessive PMNmigration can result in damaging the epithelial and
endothelial barrier and can therefore perpetuate lung injury [3,4].
Out of eleven PDE isoenzymes, PDE4 plays a pivotal role in inflammation [5]. PDE4 de-
grades exclusively cyclic adenosine monophosphate (cAMP) and 4 subtypes (A-D) are speci-
fied; each with a special nonredundant role in the control of cell function [5]. PDE4B and
PDE4D dominate in immune cells, especially in PMNs [6]. Studies in knockout mice further
revealed different functions of PDE4D and B for inflammation. PDE4B knockout, but not
PDE4D, decreased the LPS-stimulated TNFα production in monocytes and peritoneal macro-
phages [7,8]. On the contrary, Ariga et al. showed evidence that in vitro, PDE4B and PDE4D
have complementary effects on PMNmigration, one major hallmark of acute pulmonary in-
flammation [9]. Thereby, PDE4D is mainly responsible for the side effects of the PDE4-block-
ers and causes emesis and nausea [10]. Because of these, clinical trials with the PDE4-inhibitor
rolipram were stopped. PDE4-inhibitors specifically inhibit the enzyme PDE4, including all
subtypes [11–13]. The second generation PDE4-inhibitor roflumilast is the first oral obtainable
PDE4-inhibitor to treat chronic obstructive pulmonary disease (COPD) associated with a
chronic bronchitis and asthma [14,15]. In the first clinical studies, roflumilast was able to im-
prove lung function and to reduce the exacerbation of COPD [16]. The side effects were char-
acterized with a very mild nausea, diarrhea and a light headache [17]. Therefore, we chose
roflumilast and the precursor rolipram since roflumilast is already used in humans and in-
creases the clinical impact of our study.
We thought to characterize the effects of the specific PDE4-inhibitors rolipram and roflumi-
last in terms of PMNmigration into the different compartments of the lung, release of chemo-
tactic chemokines, microvascular permeability and thereby focus on the effect of the inhibitors
on pulmonal epithelial barrier. Additionally, we characterized the distribution of the PDE4B
and PDE4D subtypes on the lung epithelium and their effects on the inflammatory response.
Methods and Material
Animals
C57BL/6 male mice were obtained from Charles River Laboratories (Germany) and were 8 to
12 weeks old. All animal protocols were approved by the Animal Care and Use Committee of
the University of Tübingen.
PDE4-inhibitors
After preliminary dose-depending studies, rolipram (1mg/kg) (Sigma-Aldrich; Germany) or
roflumilast (500 μg/kg) (LGM Pharma; USA) were applied intraperitoneally [18–20] 1h after
LPS inhalation (n = 6).
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Murine model of acute lung injury
As previously described from our lab, 4 to 8 animals inhaled nebulized LPS from salmonella
enteritidis (Sigma-Aldrich) (a total of 7 ml, 500μg/ml) in a custom made chamber [21]. LPS in-
halation led to an acute pulmonary inflammation with reproducible migration of PMNs into
the different compartments of the lung—accumulation intravascular, interstitial, and alveolar
migration [22]. Microvascular permeability, chemokine release, and inflammatory changes of
receptor expressions are also triggered [23,24]. Control mice were exposed to saline aerosol.
Immunohistochemistry
Animals were treated with rolipram or roflumilast. Control mice received the solvent. Lungs
were prepared as described previously (n = 4) [24].
In vivo migration assay
24h after LPS inhalation, we determined PMNmigration into the different compartments of
the lung (intravascular, interstitial, alveolar space) via a flowcytometry-based method as de-
scribed in detail before [21]. Fluorescent GR-1 (clone RB6-8C5) was injected into the tail vein
of mice to mark all intravascular PMNs. The lungs were perfused free of blood to remove non-
adherent leukocytes from the pulmonary vasculature. PMNs from the alveolar space were ob-
tained by Bronchial lavage (BAL). Lungs were homogenized and incubated with fluorescent
antibodies to CD45 (clone 30-F11) and 7/4 (clone 7/4). Intravascular PMNs were now identi-
fied as CD 45+, 7/4+, GR1+, whereas interstitial PMNs were assigned as CD 45+, 7/4+, and
GR1- cells. Absolute cell counts were determined in the BAL and lungs (groups without LPS in-
halation n = 4; other groups n6; different time points of PDE4 inhibitor administration
n = 6).
Nebulization of PDE4-inhibitors
PDE4-inhibitors were dissolved in NaCl and nebulized, so that animals received the same
amount of the agents topical (neb) compared to ip (n5).
PDE4B and PDE4D expression and protein level
We determined the expression of PDE4B and PDE4D in lungs of mice by RT-PCR (n7). The
method was performed as described [23] with the following primers PDE4B (5`-ATC ACC
TTG CTG TGG GAT TC -3`and 5`-AAC CAA CCT GGG ATT TTT CC -3`), which detects
splice variants of PDE4B a, b, c, d, e, f, g, X1, X2, X3, X5. PDE4D (5`-CAA GTT TCA GGC
TGG CTT TC -3`and 5`- GTC CCA TGT GTG ACA AGC AC -3`) amplifies the splice vari-
ants 1, 2, 3, 4, 5, 6, 7, 8, 9, X1, X2, X4, X5. Western blots were performed as specified previously
(n = 4) [24] and analysed using imageJ, a public program being developed at the National Insti-
tutes of Health to officially analyse scientific images.
Microvascular leakage
To investigate differences between rolipram and roflumilast in terms of their effect on the cap-
illary leakage, Evans blue (20mg/kg; Sigma Aldrich, Steinheim, Germany) was injected into the
tail vein 6 h after LPS exposure (n6). 30 minutes later, thoracotomy was performed by flush-
ing the lungs with saline into the beating heart, intravascular Evans blue in the lungs was re-
moved, lungs were homogenized, Evans blue was extracted by formamide and the final
concentration was determined colorimetrically [21,23].
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Chemokine release
3 hours after LPS inhalation, the release of CXCL 1, CXCL 2/3, tumor necrosis factor-α
(TNFα), and interleukin-6 (IL-6) were measured in the BAL of mice (n6) [23].
PDE activity in the lung
To measure the enzyme activity of PDE, lungs of mice treated with rolipram/roflumilast or
controls were removed 6.5 h after LPS exposure (control without LPS n = 4; other group n = 6).
Lungs were flushed and homogenized with homogenization buffer consisting of 30 mM
HEPES and 0,1% Triton X-100 (a total volume of 4 μl per mg lung) [25]. 10 min centrifugation
at 13.000 g were followed and 10 μl lung homogenate were mixed with 190 μl PDE-assay buffer
consisting of 137 mMNaCl; 2,7 mM KCL; 8,8 mM Na2HPO4; 1,5 mM KH2PO4; 1 mM CaCl2;
and 1mMMgCl2. The reaction was started by adding 1 μM cAMP, followed by 10 min at 37°C
incubation. 3 min boiling stopped the reaction. After centrifugation at 12.000g for 30 min, the
cAMP concentrations—as an indication for PDE activity—in the supernatants were measured
using a high-performance liquid chromatography (HPLC). Representative peaks were identi-
fied and quantified using a standard curve. PDE activity was calculated reciprocally.
In separate experiments, animals were treated with 3-isobutyl-1-methylxanthine (IBMX)
(6.6mg/kg) 1h after LPS ip. Since IBMX is an unspecific PDE-inhibitor, we determined the im-
pact of IBMX and rolipram/roflumilast on the PDE activity to compare the rate of the PDE4
activity with the whole PDE activity of the lung (n = 5).
In vitro PMNmigration
We performed the in vitro transmigration assay of human PMNs through a monolayer of
NCI-H441 cells (ATCC, USA) (n2) to separate the effects of the PDE4-inhibitors on PMNs
and epithelium [23]. Epithelium or PMNs were incubated with rolipram or roflumilast for
60 min at indicated concentrations (n4). Until reaching confluence, human epithelial cells
were cultivated on inserts of a transwell system (3.0μm pore size, 6.5mm diameter; Costar,
Cambridge, MA, USA). Isolated human PMNs (Percoll gradient; GE Healthcare Bio-Sciences
AB, Uppsala, Sweden) migrated through the monolayer of epithelial cells along a chemotactic
gradient (CXCL2/3; 200ng/ml; Pepro Tech, Hamburg, Germany). By determination of myelo-
peroxidase were migrated PMNs quantified (absorption length: 405 nm).
Cytoskeletal remodeling on epithelial cells
We investigated the formation of stress fibers in human epithelial cells to characterize the effect
of the PDE-inhibitors on cell remodeling as described [26]. Treatment was blinded for analyses
of slides.
Expression of PDE4B and PDE4D on epithelial cells
H441 cells were incubated with rolipram 100 μM or roflumilast 10 μM for 1 h, and then stimu-
lated with LPS. Rabbit polyclonal anti-PDE4B and goat polyclonal anti-PDE4D were used as
primary antibody (Santa Cruz). Images were visualized using a confocal microscope (LSM 510,
Meta, Carl Zeiss). Images were analyzed using ZEN 5.0. Treatment was blinded for analyses of
slides. Images are representatives of 3 experiments.
To further confirm results from microscopy, we additionally performed western blots from
pulmonary epithelial cells and determined the impact of rolipram/roflumilast on PDE4B and
PDE4D expression. Western blots were performed as described above.
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Statistical analysis
Data are presented as mean ± SD unless indicated otherwise. Statistical analysis was performed
using GraphPad Prism version 5.3 for Windows (GraphPad Software, San Diego, CA, USA).
Differences between the groups were evaluated by one-way ANOVA followed by Bonferroni
post hoc test. P< 0.05 was considered statistically significant.
Results
Time-dependent administration of rolipram and roflumilast
We investigated the time optimum for the administration of rolipram and roflumilast by quan-
titative determination of PMNs into the alveolar space of mice. Rolipram reduced PMN counts
in the alveolar space significantly when administered either 1h before the inflammation or 1h
afterwards (1h before LPS: 1.6±0.2x106; 1h after LPS: 1.6±0.2x106 vs. 2.3±0.2x106; P< 0.05),
indicating an effect on transepithelial migration (Fig 1A). To increase the clinical impact of our
study, we chose 1h after LPS as time point for rolipram administration for all
following experiments.
Roflumilast reduced migrated PMNs into the bronchoalveolar lavage (BAL) significantly at
any time point, indicating a pivotal role of roflumilast on the epithelium (Fig 1B). PMN counts
were even significantly more decreased 1h before and 1h after LPS compared to other time
points (1h before LPS: 1.5±0.1x106; 1h after LPS: 1.4±0.1x106; 3h after LPS: 2.0±0.1x106; 6h
after LPS: 2.0±0.4x106 vs. 2.4±0.3x106; all P< 0.05). According to the administration of roli-
pram, we chose to inject roflumilast 1 h after LPS inhalation in all subsequent experiments.
Immunohistochemistry
PMNs were labeled with a specific antibody so that they appear brown in histology (Fig 2).
Without an inflammatory stimulus, the PDE4-inhibitors rolipram and roflumilast did not lead
to any changes. LPS inhalation caused a qualitative increase of PMNs into the lung. Alveolar
septa were increasingly edematous and thickened (0.4±0.11 vs. 0.14±0.07 mm; P< 0.05) lead-
ing to a destroyed lung architecture. Rolipram administration resulted in a reduced migration
of PMNs into the lung, alveolar septa were slender (0.2±0.04mm; P< 0.05) and lung architec-
ture restored. Roflumilast exceeded the effects of rolipram with a further reduction of PMN
counts, showing an almost healthy lung architecture with slim septa (0.13±0.02mm; P< 0.05).
We did not specifically quantify PMNs in histological sections since this procedure is rather in-
exact and we preferred to perform additional experiments with a flowcytometry-based method
in the following.
PDE4-dependent PMNmigration into the different compartments of the
lung
To further quantify PMN influx into the different compartments of the lung—intravascular,
interstitial, and the alveolar space, we performed the in vivo PMNmigration assay. Therefore,
PMNs were marked with specific antibodies and assigned to the different lung compartments
by flow cytometry. Rolipram or roflumilast alone did not alter PMNmigration without an in-
flammatory stimulus in any compartment (Fig 3A). After LPS inhalation, PMNs attached to
the endothelium in the intravascular compartment rose significantly (3.9±1.1x106 vs. 1.6±
0.7x106; P< 0.05). Rolipram prevented any increase at all (1.8±1.0x106; P< 0.05), whereas
roflumilast did not alter intravascular PMN counts (4.0±1.5x106). In the interstitium of the
lung, LPS caused an increase of migrated PMNs in all groups (all P< 0.05), but to a significant-
ly lesser extend in the PDE4 inhibited groups (rolipram: 2.3±0.5x106; roflumilast: 2.6±0.3x106
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Fig 1. Time optimum for the administration of rolipram (A) and roflumilast (B). The PDE4-inhibitors were given at indicated time points and 24h after
LPS inhalation, migration of PMNs into the alveolar space (BAL) was evaluated. Data are presented as mean ± SD; n = 6; *P < 0.05 vs. control without LPS;
#P < 0.05 vs. control with LPS; °P < 0.05 vs. 3 and 6h after LPS.
doi:10.1371/journal.pone.0121725.g001
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vs. 3.7±0.7x106; all P< 0.05). The inflammation augmented PMN counts in the alveolar space
in all groups (P< 0.05). Both PDE4-inhibitors had a strong effect on transepithelial migration,
but roflumilast outplayed the effect of rolipram (rolipram: 1.5±0.5x106; roflumilast: 1.2±
0.2x106 vs. 2.7±0.5x106; P< 0.05), confirming our findings from immunohistochemistry.
Nebulization of the PDE4-inhibitors
To further determine the clinical impact of rolipram and roflumilast for the treatment of
ARDS, the PDE4-inhibitors were applied topically by nebulization (Fig 3B). Ip and topical ad-
ministration of roflumilast reduced PMN counts in the BAL significantly more compared to
rolipram (roflumilast ip: 1.4±0.1x106; roflumilast neb: 1.6±0.0x106 vs. rolipram ip: 1.8±
0.2x106; rolipram neb: 1.8±0.1x106; all P< 0.05), highlighting again the strong effect of roflu-
milast on the epithelium and emphasizing the opportunity of topical administration with the
possibility of decreasing side effects.
The effect of the PDE4-inhibitors on chemokine release
We determined chemokine concentrations in the BAL since they are the attractants for PMNs
to migrate transepithelial. Without LPS inhalation, neither rolipram nor roflumilast altered
Fig 2. Impact of PDE-inhibitors on PMN infiltration into the lungs identified by immunohistochemistry.Neutrophils were stained with a specific marker
and appear brown in histology (rat anti-mouse neutrophil, clone 7/4) (original magnification, x63). Images are representatives of n = 4 experiments. Alveolar
septa of the different conditions were measured. Data are presented as mean ± SD; n = 6; *P < 0.05 vs. control without LPS; #P < 0.05 vs. control with LPS;
°P < 0.05 vs. rolipram.
doi:10.1371/journal.pone.0121725.g002
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chemokine release compared to control and are therefore displayed as one bar in the figure
(Fig 4). LPS inhalation caused a significant rise of the chemokines CXCL1, CXCL2/3, TNFα,
and IL6. PDE-inhibitors significantly decreased CXCL1, CXCL2/3, TNFα, and IL6 to a compa-
rable amount. Roflumilast diminished CXCL1—the PMN chemoattractant secreted by the epi-
thelium—even further compared to rolipram (2676±571 vs. 3358±576 pg/ml; P< 0.05),
confirming our findings from the in vivo migration assay with lowest PMN counts after roflu-
milast treatment and emphasizing an outstanding role of roflumilast on the epithelium.
The impact of PDE4-inhibitors on microvascular permeability
We determined microvascular permeability by means of Evans blue extravasation technique.
Without LPS inhalation, the PDE4-inhibitors did not alter Evans blue extravasation (Fig 5).
LPS caused a significant increase of the capillary leakage in all groups (LPS: 246±19; rolipram:
Fig 3. Effect of rolipram and roflumilast on PMNmigration into the lung. PDE4-inhibitors were injected
and migration of PMNs into the different compartments of the lung without and with LPS (IV = intravascular;
IS = intersitital; BAL = alveolar space) quantified (A). In additional experiments, the effects of nebulization the
PDE4-inhibitors on PMNmigration were analyzed (ip = intraperitoneally, neb = nebulized) (B). Data are
presented as mean ± SD; figure A: n = 4 without LPS; n = 8 with LPS; figure B: n4; *P < 0.05 vs. control
without LPS; #P < 0.05 vs. control with LPS inhalation; °P < 0.05 vs. rolipram ip.
doi:10.1371/journal.pone.0121725.g003
Fig 4. Chemokine levels in the BAL are reduced by rolipram and roflumilast. LPS inhalation increased all chemokine levels and the administration of the
PDE4-inhibitors decreased this effect. Data are presented as mean ± SD; n = 4 without LPS; n6 with LPS; *P < 0.05 vs. control without LPS; #P < 0.05 vs.
control with LPS inhalation; °P < 0.05 vs. rolipram.
doi:10.1371/journal.pone.0121725.g004
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190±61; roflumilast: 137±73 vs. 45±18 μg/g lung; all P< 0.05). Both PDE4-inhibitors reduced
microvascular permeability significantly, but roflumilast demonstrated a significantly stronger
effect on stabilization the capillary barrier.
Effects of rolipram and roflumilast on the expression of PDE4B and
PDE4D in the lung
LPS inhalation caused a significant increase of the expression of the inflammatory PDE4B
(5.9±2.9 vs. 1.1±0.4; P< 0.05) (Fig 6A). Rolipram and roflumilast decreased the expression
about a comparable amount (rolipram: 3.2±1.7; roflumilast: 3.9±1.6; all P< 0.05), reflecting
their anti-inflammatory potential in terms of inflammation. These findings were confirmed on
protein level via western blots (the whole blot is shown in S1 Fig).
LPS also increased PDE4D, but to a lesser extent (2.2±0.6 vs. 1.0±0.2; P< 0.05) (Fig 6B).
Neither rolipram nor roflumilast had influence on the expression of the enzyme, which is held
responsible for the emetic effects of the inhibitors [10]. On protein levels, the PDE4-inhibitors
reduced PDE4D protein but roflumilast less compared to rolipram, showing a presumably
temporary effect.
PDE4 activity
PDE4-inhibitors specifically increase cAMP levels by blocking the subtypes of the enzymes. We
determined PDE4 activity by using a PDE4 activity assay, where changes of cAMP levels in the
lungs of mice were measured and the activity reciprocally calculated (Fig 7A). PDE-inhibitors sig-
nificantly reduced the activity even without an inflammatory stimulus (rolipram: 1.53±0.11;
roflumilast: 1.61±0.14 vs. 2.53±0.39; all P< 0.05). LPS inhalation significantly increased the ac-
tivity of the PDE (4.75±1.93; P< 0.05) and rolipram inhibited the enzyme (2.20±0.79; P< 0.05).
But roflumilast reduced PDE4 even more effective to values comparable with the roflumilast
Fig 5. Microvascular permeability was attenuated by PDE4-inhibitors. 6h after LPS inhalation, the capillary leakage was assessed by Evans blue
extravasation. Data are presented as mean ± SD; n = 6; *P < 0.05 vs. control without LPS; #P < 0.05 vs. control with LPS inhalation; °P < 0.05 vs. rolipram.
doi:10.1371/journal.pone.0121725.g005
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Fig 6. Gene expression and protein levels of PDE4B and PDE4D in lungs of mice. The impact of
rolipram and roflumilast on transcription and translation of PDE4B (A) and PDE4D (B) was determined in the
lungs of mice. Data are presented as mean ± SD; n = 6 without LPS; n7 with LPS; representative Western
Phosphodiesterase4 on Epithelial Cells in Acute Pulmonary Inflammation
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group without LPS (1.72±0.4; P< 0.05), reflecting the higher anti-inflammatory potential of
roflumilast in terms of PMNmigration, chemokine levels and microvascular permeability.
blot analyses of four independent experiments (for whole western blots see S1 Fig); *P < 0.05 vs. control
without LPS; #P < 0.05 vs. control with LPS inhalation.
doi:10.1371/journal.pone.0121725.g006
Fig 7. The effect of inflammation and rolipram/roflumilast on PDE activity (A).Mice were treated with roflumilast or rolipram and inflammation induced
by LPS inhalation. Lung homogenates were prepared for PDE4 activity. PDE4-inhibitors decreased the activity of the enzyme even without inflammation.
Data are presented as mean ± SD; groups without LPS n4; groups with LPS n = 6; *P < 0.05 vs. control without LPS; #P < 0.05 vs. control with LPS
inhalation. The impact of the unspecific PDE-inhibitor 3-isobutyl-1-methylxanthine (IBMX) on the PDE activity compared to the PDE4-inhibiors (B). Mice
inhaled LPS and were treated with PDE4-inhibiors or IBMX. Data are presented as mean ± SD; n = 5; *P < 0.05 vs. IBMX group.
doi:10.1371/journal.pone.0121725.g007
Phosphodiesterase4 on Epithelial Cells in Acute Pulmonary Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0121725 April 24, 2015 12 / 25
PDE activity after rolipram and roflumilast were both significantly higher compared to the
global PDE-inhibitor IBMX (rolipram: 1.3±0.1; roflumilast: 1.4±0.4 vs. 1±0.2; all P< 0.05) (Fig
7B). Roflumilast and rolipram inhibit PDE4 activity 28% less compared to IBMX. Thereby,
IBMX is additionally an unspecific but effective adenosine receptor antagonist [27], which
leads to additional changes in cAMP-levels not only correlated with PDE activity. Nevertheless,
PDE4 seems to play a predominant role in the lungs in terms of inflammation.
In vitro transmigration assay
In this assay, isolated human PMNs migrate along a chemotactic gradient through a monolayer
of pulmonary epithelial cells. With the in vitro transmigration assay it is possible, to separate
the impact of the PDE4-inhibitors on PMNs and on the epithelium. Treated PMNs at certain
concentrations migrated significantly less through a monolayer of epithelium (Fig 8). The ex-
clusive treatment of the epithelium was also effective in curbing down PMNmigration, where-
as roflumilast was still effective at lower concentrations, highlighting a direct pivotal role of the
PDE4-inhibitors on stabilization the epithelium (all P< 0.05).
Cytoskeletal remodeling
To evaluate the effect of the PDE4-inhibitors on cytoskeletal remodeling as one critical param-
eter of pulmonary barrier function, we stained F-actin in pulmonary epithelial cells (Fig 9).
The PDE-inhibitors did not alter cytoskeletal remodeling without an inflammatory stimulus.
LPS-induced stress fibers, which are an essential requirement for a direct migration of PMNs
into the alveolar space. Roflumilast and also, but less prominent, rolipram reduced these stress
fibers, indicating their pivotal role on epithelial barrier function and confirming our in vitro
transmigration assay.
PDE4B and PDE4D distribution on epithelial cells
To further evaluate PDE4B and PDE4D on epithelial cells, we determined the distribution of
the two enzymes in pulmonary epithelial cells with fluorescent staining. First, we investigated
the impact of rolipram and roflumilast on the expression of the two subtypes of PDE4 individ-
ually and measured the light intensity of the enzymes. There were no differences in between
the groups without an inflammation. LPS increased PDE4B protein in epithelial cells, whereas
rolipram and to a higher extend roflumilast significantly reduced protein levels (roflumilast:
104±13; rolipram: 139±12; control: 171±12; all P< 0.05) (Fig 10), indicating the pivotal role of
the PDE-inhibitors on epithelial cells. These findings were further confirmed by western blots
(Fig 11) and further verify our data from gene and protein expression of PDE4B in the lungs of
mice. LPS also enhanced PDE4D protein, but to a lesser degree as PDE4B (Fig 12). Rolipram
and roflumilast did not alter PDE4D protein levels, which was also confirmed via western blots
(Fig 13) (see S2 Fig for whole blots). In separate experiments, we stained PDE4B and PDE4D
in one sample to investigate the effect of LPS on the distribution of both enzymes (Figs 14 and
15). Even at first glance, it is striking that in the picture without LPS PDE4D (green) is domi-
nant, whereas LPS increased predominantly PDE4B (red), confirming our previous findings.
Both subtypes were found coexistent around the nucleus and also in the cytoplasm.
Discussion
We chose to investigate the impact of roflumilast compared to rolipram on the epithelium in
LPS-induced pulmonary inflammation since roflumilast is already licensed for the use in hu-
mans and its precursor rolipram was used in most experimental studies so far. In the last years,
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the discussion in the literature pointed into investigating a selective PDE4B-inhibitor [14,28]
to reduce the side effects associated with PDE4D-inhibition [10,29]. In 2013, Suzuki et al.
brought new insight on this topic [30]. They compared a selective PDE4B compound with
roflumilast in terms of the efficiency of reducing pulmonary neutrophilia, the reduction of
TNFα, and gastric adverse effects. The impact of the selective PDE4B compound on pulmonary
neutrophilia was weaker and finally, at higher concentrations of the compound and then com-
parable therapeutic effects, the specific PDE4B inhibitor was not superior related to gastric side
effects compared to the unspecific inhibitor roflumilast. The authors still suggested that
PDE4D is involved in gastric side effects of PDE4-inhibitors, since the inhibitory potency on
gastric emptying of the specific compound was slighter.
The most feasible explanation for the weaker developed impact of the specific PDE4B com-
pound on PMNmigration is that PDE4D has also anti-inflammatory properties. This explana-
tion is supported by the findings of Ariga et al., where PDE4D also interfered with PMN
migration into the lung [9]. In their study, the administration of rolipram to PDE4B knockout
Fig 8. In vitro transmigration assay of human PMNs through a pulmonary epithelial monolayer. PMNs or epithelium were treated with rolipram/
roflumilast and migration of PMNs through human epithelium measured. Migration of PMNs was initiated through the chemokine CXCL2/3 in all wells. Data
are presented as mean ± SD; n4; *P < 0.05 vs. control.
doi:10.1371/journal.pone.0121725.g008
Fig 9. The impact of PDE4-inhibitors on cytoskeletal remodeling. LPS-induced formation of F-actin (green) in human pulmonary epithelial cells.
Rolipram and roflumilast reduced cytoskeletal remodeling, whereas the effect was more intense in roflumilast treated cells. Images are representatives of
three experiments with similar results (original magnification, x63).
doi:10.1371/journal.pone.0121725.g009
Phosphodiesterase4 on Epithelial Cells in Acute Pulmonary Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0121725 April 24, 2015 15 / 25
Fig 10. The effect of LPS and rolipram/roflumilast on PDE4B protein expression in epithelial cells.Human pulmonary epithelial cells were pretreated
with rolipram/roflumilast and the influence of LPS on the expression of PDE4B (green) (A) investigated. Images are representatives of four experiments with
similar results (original magnification, x63). Data are presented as mean ± SD; n = 3; *P < 0.05 vs. control group without LPS inhalation, #P < 0.05 vs. control
with LPS; °P < 0.05 vs. the rolipram group.
doi:10.1371/journal.pone.0121725.g010
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mice still had an additional anti-inflammatory effect on PMNmigration and, in addition,
PDE4D knockout mice also showed reduced PMN counts after LPS-induced acute pulmonary
inflammation. At first sight, this stays in contrast with studies that attributed only PDE4B an
influence on LPS-induced TNFα production of monocytes and macrophages [7,8]. Suzuki
et al. hypothesized that PDE4B predominantly inhibits TNFα production for chemotaxis, but
for the inhibition of the actual PMNmigration blocking both subtypes PDE4B and PDE4D is
necessary [30]. In the presented study, we were able to ascribe the specific PDE4-inhibitors the
influence on the reduction of gene and protein expression of PDE4B in the lungs of mice, while
Fig 11. PDE4B protein expression in epithelial cells after LPS and rolipram/roflumilast treatment. To further confirm results frommicroscopy, we
additionally performed western blots of the PDE4B of H441 cells. Images are representatives of four experiments with similar results (original magnification,
x63). Data are presented as mean ± SD; n = 3; *P < 0.05 vs. control group without LPS inhalation, #P < 0.05 vs. control with LPS; °P < 0.05 vs. the
rolipram group.
doi:10.1371/journal.pone.0121725.g011
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Fig 12. The effect of LPS and rolipram/roflumilast on PDE4D protein expression in epithelial cells.Human pulmonary epithelial cells were pretreated
with rolipram/roflumilast and the influence of LPS on the expression of PDE4D (green) (B.1) evaluated. Images are representatives of four experiments with
similar results (original magnification, x63). Data are presented as mean ± SD; n = 3; *P < 0.05 vs. control group without LPS inhalation, #P < 0.05 vs. control
with LPS.
doi:10.1371/journal.pone.0121725.g012
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at the same time, not influencing the expression of PDE4D. We further determined the distri-
bution of the PDE4B and PDE4D enzyme in pulmonary epithelial cells and were able to show
the incremental role of PDE4B over PDE4D in LPS-stimulated epithelial cells. Rolipram, and
even more intense roflumilast, reduced PDE4B expression, while not influencing PDE4D. The
effect on protein levels can most probably be explained as temporary effect.
Further on, it can be hypothesized that roflumilast stabilizes pulmonal epithelial cells during
inflammation better compared to rolipram due to decreased PDE4B. But in vivo and in vitro,
LPS increased both subtypes. In contrast with our findings, nontypeable haemophilus influez-
nae (NTHi)-induced inflammation increased only PDE4B expression, but not PDE4D [31].
Fig 13. PDE4D protein expression in epithelial cells after LPS and rolipram/roflumilast treatment. To further confirm results frommicroscopy, we
additionally performed western blots of the PDE4B of H441 cells. Images are representatives of four experiments with similar results (original magnification,
x63). Data are presented as mean ± SD; n = 3; *P < 0.05 vs. control group without LPS inhalation, #P < 0.05 vs. control with LPS.
doi:10.1371/journal.pone.0121725.g013
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Fig 14. The distribution of PDE4B and PDE4D protein in epithelial cells. PDE4B and PDE4D were stained in one sample. Without LPS, PDE4D (green)
is dominant. Both subtypes were found coexistent around the nucleus and also in the cytoplasm. Images are representatives of four experiments with similar
results (original magnification, x63).
doi:10.1371/journal.pone.0121725.g014
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Fig 15. The influence of hyperinflammation on PDE4B and PDE4D protein expression in epithelial cells. PDE4B and PDE4D were stained in one
sample to investigate the effect of LPS on the distribution of both enzymes. Even at first glance, it is striking that in the picture without LPS PDE4D (Fig 14) is
dominant, whereas LPS increased predominantly PDE4B (red) (Fig 15), confirming our previous findings. Images are representatives of four experiments
with similar results (original magnification, x63).
doi:10.1371/journal.pone.0121725.g015
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NTHi-induced inflammation acts via the TLR2 pathway, LPS via the TLR4 pathway. In the
presented study, we detected an increase of PDE4D expression through LPS, which was also
found by Gobjishvili et al. in primary hepatic stellate cells [32]. In our model, rolipram and
roflumilast did not have any influence on PDE4D expression, suggesting that the side effects of
the PDE4-inhibitors might depend on the signal cascade of the underlying disease causing the
administration of the PDE4-inhibitors.
PDE4B is known to reduce TNFα levels [7,8,30], but most of the authors did not determine
other chemokines than TNFα. In the presented study, we also detected the impact of roflumi-
last and rolipram on the potent chemoattractant TNFα and we further investigated and discov-
ered their pivotal role in the reduction of the release of CXCL1, CXCL2/3, and IL-6. These
chemokines are the most potent chemoattractants for neutrophils, and so far have not been in-
vestigated in terms of the use of PDE4-inhibitors. TNFα and IL6 induce neutrophil adhesion to
the endothelium by increasing the adhesion molecules VCAM-1 (vascular cell adhesion mole-
cule) and ICAM-1 (intercellular adhesion molecule) [33]. We did not detect any differences be-
tween the PDE4-inhibitors in terms of TNFα and IL6 reduction, which could explain why
there were no differences concerning interstitial PMN counts between the two compounds.
CXCL1 and CXCL2/3 are released in the BAL as the major chemoattractants for PMNs
[34,35]. However, CXCL1 is not only expressed by neutrophils but also by the epithelium
[35,36], highlighting the pivotal role of PDE-inhibitors on the epithelium. The lower CXCL1
levels in roflumilast treated animals explain and confirm our findings from the in vivo and in
vitro transmigrationassay with a stronger effect of the compound in terms of reducing PMN
migration transepithelial into the alveolar space.
Besides the reduction of CXCL1, an additional potential mechanism shown in the presented
study might be the reduction of cytoskeletal remodeling by the PDE4-inhibitors, indicating
their pivotal role in stabilization pulmonary barrier function. Underlying our findings of PDE-
inhibitors influencing the epithelium, Moodley et al. determined the impact of PDE4-inhibitor
in combination with inhaled corticosteroids and β2-adrenoreceptor agonists on pulmonary
bronchial epithelium in terms of COPD in vitro [37]. PDE4-inhibitors further augmented the
expression of glucocorticoid-induced genes in the epithelium.
In the presented study, roflumilast had a superior outcome on transepithelial PMNmigra-
tion compared to rolipram. In relation to the second hallmark of acute pulmonary inflamma-
tion—microvascular permeability—we also detected a pivotal role of roflumilast on
stabilization the capillary leakage. This last finding is in accordance with the findings of Sanz
et al. [38], where roflumilast showed stronger effects in terms of E-selectin expression of stimu-
lated endothelial cells and neutrophil CD11b expression, a cell surface marker required
for transmigration.
The use of inhaled agents is well established in respiratory diseases to increase the local con-
centration of the compound associated with lower systemic concentrations and therefore
weaker side effects. Recently, Jin et al. demanded the topical administration of PDE4-inhibitors
as a potential to minimize side effects [5] and Zimmermann et al. detected that rolipram treat-
ment significantly decreased epithelial microwound closure and defined rolipram as contrain-
dicated for the use in chronic inflammatory bowel disorders [39]. To our knowledge, we are
the first to demonstrate that nebulized rolipram and roflumilast have anti-inflammatory prop-
erties with the same effect on PMNmigration. This finding highlights the clinical potential of
roflumilast and has the potency to reduce gastrointestinal side effects. The other clinically im-
portant insight of the presented study is that roflumilast still showed anti-inflammatory effects
even when given six hours after the inflammatory stimulus.
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Conclusions
In a LPS-induced model of pulmonary inflammation, PDE-inhibitors prevented transendothe-
lial and transepithelial PMNmigration into the different compartments of the lung. The pre-
dominant effect of roflumilast on stabilizing the alveolocapillary barrier was also pivotal on
pulmonary epithelium. LPS inhalation induced the expression of PDE4B and PDE4D, but
PDE-inhibitors reduced the inflammatory PDE4B and only slightly affected the mainly emetic-
acting PDE4D. Furthermore, we highlighted the clinical impact of roflumilast since it still
showed anti-inflammatory properties when administered after the inflammatory stimulus, and
additionally topical administration as a possibility to reduce side effects has also been effective.
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S1 Fig. Whole western blots of cropped bands of PDE4B, PDE4D and GAPDH shown in
Fig 6.
(TIF)
S2 Fig. Whole western blots of cropped bands from Fig 10A.2 and 10B.2 of PDE4B and
PDE4D expression in pulmonary epithelial cells. 1 = control; 2 = control+LPS; 3 = rolipram+
LPS; 4 = roflumilast+LPS.
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